Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622407 | 0.90 | SCD (0.82) | SCD | |
| SCHEMBL12836448 | 0.85 | SCD (0.73) | SCD | |
| SCHEMBL14870428 | 0.83 | SCD (0.70) | SCD | |
| SCHEMBL31162759 | 0.82 | SCD (0.70) | SCD | |
| SCHEMBL3467538 | 0.82 | SCD (0.69) | SCD | |
| SCHEMBL4255462 | 0.81 | SCD (0.68) | SCD | |
| SCHEMBL31162566 | 0.80 | SCD (0.67) | SCD | |
| SCHEMBL4265657 | 0.80 | SCD (0.67) | SCD | |
| SCHEMBL13777958 | 0.79 | SCD (0.66) | SCD | |
| SCHEMBL4162084 | 0.79 | SCD (0.65) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| US-20240325385-A1 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SCD1 INHIBITOR AND USE THEREOF | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2024-10-03 | — | — | US | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| US-20230414626-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-28 | — | — | US | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| CN-116568330-A | Iron death induction for cancer treatment | 纪念斯隆-凯特琳癌症中心 | 2023-08-08 | — | — | CN | claimed |
| WO-2023108563-A1 | ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING EZH2 INHIBITOR AND SD1 INHIBITOR AND USE THEREOF | 北京大学第三医院（北京大学第三临床医学院） | 2023-06-22 | — | — | WO | claimed |
| CN-115607547-A | Modeling medicine for meibomian gland dysfunction animal model, construction method and application | 厦门大学 | 2023-01-17 | — | — | CN | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114177299-A | Antitumor pharmaceutical composition containing EZH2 inhibitor and SCD1 inhibitor and application thereof | 北京大学第三医院（北京大学第三临床医学院） | 2022-03-15 | — | — | CN | claimed |
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-20180042925-A1 | METHODS FOR TREATING CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-02-15 | — | — | US | claimed |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250334596-A1 | ISOTOPIC LABELS FOR QUANTITATIVE MASS SPECTROMETRY OF LIPID ISOMERS | TEXAS A & M UNIV SYS (US) | 2025-10-30 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | SCD 145/4885 |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | SCD 568/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | SCD 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.